Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Is Moderna Stock a Buy at This Price?

By Brian Orelli, PhD - Oct 20, 2020 at 9:40AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Here's what it takes to justify the current valuation.

Moderna's ( MRNA -4.36% ) market cap has more than quadrupled since the beginning of this year on hopes that its coronavirus vaccine will protect people from COVID-19. In this Fool Live video, Healthcare and Cannabis Bureau Chief Corinne Cardina and longtime Motley Fool contributor Brian Orelli discuss what it takes to justify the current valuation. Ultimately, it may come down to how often we need to take the vaccine.

Corinne Cardina: TradeSeeker would like to know if Moderna is on our list. Moderna's not on our treatment list but Moderna will be on our COVID-19 vaccine candidate list. Brian, do you have any thoughts on Moderna?

Brian Orelli: I think it's overpriced, but I also thought it was overpriced half a market cap ago. So don't necessarily look at me. Don't go selling because I said so because I was wrong all this time.

Again, I think that whether it's valued properly right now is going to mostly depend on whether you have to be retreated with their vaccine. They have other treatments too but I think those are longer-term plays.

The issue is going to be, is the company going to make $5 billion, $10 billion, and then stop selling the thing? If that's the case, it's hard to justify their market cap. I don't know what it's at right now. The ticker there is MRNA in case anybody wants to know. It's $28 billion market cap right now.

At a five price-to-sales ratio, then that's justifying $6 billion in sales. But the five price-to-sales ratio -- we would want to see that $6 billion going on forever. So that five is a good number for a non-growing biotech company or pharmaceutical company. That's basically justifying $6 billion in sales forever. They could do $10 billion and then not have sales for quite a few years as they build the rest of their pipeline, which is all early stage vaccines.

Corinne Cardina: Yeah, great point. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
$352.43 (-4.36%) $-16.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.